This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

PREVYMIS® (letermovir)

Pre-emptive treatment for CMV in adult allogeneic HSCT recipients, its challenges and a possible alternative

Prescribing Information

Length: 04:52

Professor Karl Peggs, Consultant Haematologist, University College London Hospitals NHS Foundation Trust.

In this video, Professor Peggs talks about established pre-emptive treatment strategies for cytomegalovirus (CMV) reactivation in haematopoietic stem cell transplant patients and their limitations. Prophylaxis offers additional benefits compared with pre-emptive treatment options, however characteristics of current antivirals limit their use to pre-emptive therapy. The ideal characteristics of a prophylaxis agent for CMV are discussed.

Supporting documentation

GB-CYT-00189 | Date of Preparation: February 2020